Callan Family Office LLC Invests $35,000 in Nautilus Biotechnology, Inc. $NAUT

Callan Family Office LLC acquired a new position in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 48,894 shares of the company’s stock, valued at approximately $35,000.

Other institutional investors have also bought and sold shares of the company. Presidio Capital Management LLC boosted its stake in Nautilus Biotechnology by 246.6% in the 2nd quarter. Presidio Capital Management LLC now owns 34,664 shares of the company’s stock valued at $25,000 after buying an additional 24,664 shares in the last quarter. XTX Topco Ltd acquired a new stake in Nautilus Biotechnology in the 1st quarter valued at $31,000. Fayez Sarofim & Co acquired a new stake in Nautilus Biotechnology in the 1st quarter valued at $39,000. Deutsche Bank AG boosted its stake in Nautilus Biotechnology by 145.2% in the 1st quarter. Deutsche Bank AG now owns 54,839 shares of the company’s stock valued at $47,000 after buying an additional 32,470 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its stake in Nautilus Biotechnology by 468.3% in the 1st quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock valued at $51,000 after buying an additional 50,871 shares in the last quarter. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Stock Down 9.3%

NAUT stock opened at $0.97 on Friday. The company has a market cap of $122.52 million, a P/E ratio of -1.87 and a beta of 1.48. Nautilus Biotechnology, Inc. has a twelve month low of $0.62 and a twelve month high of $2.97. The business has a fifty day moving average of $0.77 and a 200-day moving average of $0.76.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings data on Thursday, July 31st. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. As a group, equities research analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current fiscal year.

Insider Activity at Nautilus Biotechnology

In related news, CEO Sujal M. Patel acquired 83,500 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was acquired at an average cost of $0.68 per share, with a total value of $56,780.00. Following the completion of the purchase, the chief executive officer directly owned 10,341,721 shares in the company, valued at approximately $7,032,370.28. This trade represents a 0.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders acquired 220,000 shares of company stock worth $147,635 over the last ninety days. 41.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell” and an average target price of $2.13.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.